MK-677 vs CJC-1295

Side-by-side comparison of MK-677, CJC-1295 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute MK-677 MK-677 (Ibutamoren) — Oral GH Secretagogue Growth Hormone CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone
Basics
Molecular type Non-Peptide GH SecretagogueGHRH Analogue
Amino acids —29
Molecular weight 624.8 Da3,368.9 Da
Half-life ~24 hours30 min (without DAC) / 7–8 days (with DAC)
Route(s) OralSubcutaneous, Intramuscular
Mechanism & Research
Primary mechanism MK-677 mimics ghrelin's binding to GHSR-1a receptors, activating the same signalling cascade that endogenous ghrelin uses to stimulate GH release. As a small non-peptide molecule, it resists enzymatic degradation and is … CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi…
Research status Research Compound Research Compound
Evidence summary MK-677 has one of the most extensive clinical datasets of any non-approved GH secretagogue, with Phase 1/2 trials across multiple populations including GH-deficient adults, elderly frail patients, and post-hip-fracture p… Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs.
Protocol & Dosing
Typical dose 10–25 mg/day100–200 mcg (without DAC); 2mg every 2 weeks (with DAC)
Frequency Once daily2–3x daily (without DAC); biweekly (with DAC)
Duration 8–16 weeks; some protocols run 6 months8–16 weeks
Timing Bedtime (maximises nocturnal GH pulse; also reduces daytime appetite impact)Without DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly.
Safety
Common side effects
  • Increased appetite (often significant)
  • Water retention / oedema
  • Tingling or numbness (extremities)
  • Fatigue (initial weeks)
  • Water retention
  • Mild headache
  • Flushing (post-injection)
  • Tingling
Contraindications
  • Active malignancy
  • Uncontrolled diabetes (insulin resistance worsening)
  • Severe fluid retention conditions (CHF, severe liver disease)
  • Active malignancy
  • Uncontrolled hypothyroidism
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, CJC-1295, GHRP-6 Ipamorelin, Sermorelin, GHRP-2, Tesamorelin
Full profile Read full MK-677 profile → Read full CJC-1295 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.